ArticleJCI insight2020
Erythromycin inhibits neutrophilic inflammation and mucosal disease by upregulating DEL-1.
Article in JCI insight, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Effects of erythromycin dosage on clinical outcomes in stable non-cystic fibrosis bronchiectasis: A randomized controlled trial.Medicine · 2025Trial
- DEL-1 is an Endogenous Senolytic Protein that Inhibits Senescence-Associated Bone Loss.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Synergistic effects of biodegradable magnesium alloy and erythromycin on osteogenic activity.Journal of dental sciences · 2026Article
- Pharmacokinetic/pharmacodynamic evaluation of gamithromycin against rabbit pasteurellosis.BMC veterinary research · 2024Article
- A novel macrolide-Del-1 axis to regenerate bone in old age.iScience · 2024Article
- Developmental endothelial locus 1: the present and future of an endogenous factor in vessels.Frontiers in physiology · 2024Review
- Erythromycin Restores Osteoblast Differentiation and Osteogenesis Suppressed byPharmaceuticals (Basel, Switzerland) · 2023Article
- Neutrophil elastase aggravates periodontitis by disrupting gingival epithelial barrier via cleaving cell adhesion molecules.Scientific reports · 2022Article
- Osteoimmunology in Periodontitis: Local Proteins and Compounds to Alleviate Periodontitis.International journal of molecular sciences · 2022Review
- Overexpression of DEL-1 Downregulates SH3BP2 Expression and Inhibits Porphyromonas gingivalis-induced Gingival Inflammation In Vivo and In Vitro.Oral health & preventive dentistry · 2022Article
- Negative Regulators of Inflammation Response to the Dynamic Expression of Cytokines in DF-1 and MDCK Cells Infected by Avian Influenza Viruses.Inflammation · 2022Article
- Developmental endothelial locus-1 in cardiovascular and metabolic diseases: A promising biomarker and therapeutic target.Frontiers in immunology · 2022Review
- Clarithromycin Inhibits Pneumolysin Production via Downregulation ofMicrobiology spectrum · 2021Article
- Calprotectin (S100A8/A9) Is an Innate Immune Effector in Experimental Periodontitis.Infection and immunity · 2021Article
- Application of Ligature-Induced Periodontitis in Mice to Explore the Molecular Mechanism of Periodontal Disease.International journal of molecular sciences · 2021Review
- DEL-1: a potential therapeutic target in inflammatory and autoimmune disease?Expert review of clinical immunology · 2021Article
- Effects of Erythromycin on Osteoclasts and Bone Resorption via DEL-1 Induction in Mice.Antibiotics (Basel, Switzerland) · 2021Article
- Effects of Antibiotics upon the Gut Microbiome: A Review of the Literature.Biomedicines · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 5 countries.
Funding
Abstract
Macrolide antibiotics exert antiinflammatory effects; however, little is known regarding their immunomodulatory mechanisms. In this study, using 2 distinct mouse models of mucosal inflammatory disease (LPS-induced acute lung injury and ligature-induced periodontitis), we demonstrated that the antiinflammatory action of erythromycin (ERM) is mediated through upregulation of the secreted homeostatic protein developmental endothelial locus-1 (DEL-1). Consistent with the anti-neutrophil recruitment action of endothelial cell-derived DEL-1, ERM inhibited neutrophil infiltration in the lungs and the periodontium in a DEL-1-dependent manner. Whereas ERM (but not other antibiotics, such as josamycin and penicillin) protected against lethal pulmonary inflammation and inflammatory periodontal bone loss, these protective effects of ERM were abolished in Del1-deficient mice. By interacting with the growth hormone secretagogue receptor and activating JAK2 in human lung microvascular endothelial cells, ERM induced DEL-1 transcription that was mediated by MAPK p38 and was CCAAT/enhancer binding protein-β dependent. Moreover, ERM reversed IL-17-induced inhibition of DEL-1 transcription, in a manner that was dependent not only on JAK2 but also on PI3K/AKT signaling. Because DEL-1 levels are severely reduced in inflammatory conditions and with aging, the ability of ERM to upregulate DEL-1 may lead to a novel approach for the treatment of inflammatory and aging-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.